Childhood cancer epidemiology in the Czech Republic (1994-2016).


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
12 2020
Historique:
received: 18 06 2020
revised: 13 10 2020
accepted: 18 10 2020
pubmed: 24 11 2020
medline: 13 4 2021
entrez: 23 11 2020
Statut: ppublish

Résumé

The knowledge of cancer burden in the population, its time trends and the possibility of international comparison is an important starting point for cancer control programmes. Our study aimed to evaluate trends in childhood cancer epidemiology of patients aged 0-14 years in the period 1994-2016 in the Czech Republic. Data on childhood cancers have been obtained from the Czech National Cancer Registry. These data were validated using the clinical database of childhood cancer patients and combined with data from death certificates. Incidence and mortality trends were assessed by the joinpoint regression method. The life tables method was used to calculate the overall age-standardised five-year survival. The incidence trend was stable; the age-standardised (world) cancer incidence - ASR (W) - was 173.7 per 1 million children in the period 1994-2016. However, there was apparent significant decrease in mortality: ASR (W) dropped from 58.1 per 1 million children in 1994 to 21.4 per 1 million children in 2016. The overall five-year survival increased over time by 10 %. Statistically significant improvements in survival were observed in patients with lymphoid leukaemia, astrocytomas, neuroblastomas, osteosarcomas and rhabdomyosarcomas. Such a relevant increase in survival rates, and therefore also a decrease in mortality rates in the Czech Republic, is most likely due to improvements in diagnostic and treatment methods since the 1990s, which were facilitated by the concentration of childhood cancer patients in children's cancer centres.

Sections du résumé

BACKGROUND
The knowledge of cancer burden in the population, its time trends and the possibility of international comparison is an important starting point for cancer control programmes. Our study aimed to evaluate trends in childhood cancer epidemiology of patients aged 0-14 years in the period 1994-2016 in the Czech Republic.
METHODS
Data on childhood cancers have been obtained from the Czech National Cancer Registry. These data were validated using the clinical database of childhood cancer patients and combined with data from death certificates. Incidence and mortality trends were assessed by the joinpoint regression method. The life tables method was used to calculate the overall age-standardised five-year survival.
RESULTS
The incidence trend was stable; the age-standardised (world) cancer incidence - ASR (W) - was 173.7 per 1 million children in the period 1994-2016. However, there was apparent significant decrease in mortality: ASR (W) dropped from 58.1 per 1 million children in 1994 to 21.4 per 1 million children in 2016. The overall five-year survival increased over time by 10 %. Statistically significant improvements in survival were observed in patients with lymphoid leukaemia, astrocytomas, neuroblastomas, osteosarcomas and rhabdomyosarcomas.
CONCLUSION
Such a relevant increase in survival rates, and therefore also a decrease in mortality rates in the Czech Republic, is most likely due to improvements in diagnostic and treatment methods since the 1990s, which were facilitated by the concentration of childhood cancer patients in children's cancer centres.

Identifiants

pubmed: 33223489
pii: S1877-7821(20)30182-X
doi: 10.1016/j.canep.2020.101848
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101848

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Denisa Krejci (D)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 126/3, 62500, Brno, Czech Republic; Institute of Health Information and Statistics of the Czech Republic, Palackeho namesti 4, 12801, Prague 2, Czech Republic. Electronic address: krejcid@iba.muni.cz.

Michaela Zapletalova (M)

Institute of Health Information and Statistics of the Czech Republic, Palackeho namesti 4, 12801, Prague 2, Czech Republic.

Ivana Svobodova (I)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 126/3, 62500, Brno, Czech Republic; Institute of Health Information and Statistics of the Czech Republic, Palackeho namesti 4, 12801, Prague 2, Czech Republic.

Viera Bajciova (V)

Department of Paediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Cernopolni 9, 62500, Brno, Czech Republic.

Peter Mudry (P)

Department of Paediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Cernopolni 9, 62500, Brno, Czech Republic.

Vratislav Smelhaus (V)

Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, V Uvalu 84, 15006, Prague 5, Czech Republic.

Jaroslav Sterba (J)

Department of Paediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Cernopolni 9, 62500, Brno, Czech Republic.

Jan Stary (J)

Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital in Motol, V Uvalu 84, 15006, Prague 5, Czech Republic.

Riccardo Capocaccia (R)

Cancer Epidemiology Unit, National Center of Epidemiology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.

Ladislav Dusek (L)

Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Kamenice 126/3, 62500, Brno, Czech Republic; Institute of Health Information and Statistics of the Czech Republic, Palackeho namesti 4, 12801, Prague 2, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH